UCB Owners | StatInvestor

Health Care & Life Sciences » Biotechnology | UCB

UCB S.A. | Ownership

Companies that own UCB S.A.

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

Wellington Management Co. LLP

13,116,135

6.74%

96,280

0.23%

07/31/2018

Wellington Management International Ltd.

5,118,453

2.63%

3,127,810

8.82%

12/31/2017

The Vanguard Group, Inc.

3,206,269

1.65%

14,359

0.01%

07/31/2018

BlackRock Fund Advisors

2,565,863

1.32%

2,773

0.01%

09/06/2018

Norges Bank Investment Management

2,377,002

1.22%

393,366

0.03%

12/31/2017

Schroder Investment Management Ltd.

1,552,620

0.8%

-104,269

0.09%

05/31/2018

Lyxor International Asset Management SAS

1,189,152

0.61%

5,704

0.05%

09/05/2018

M&G Investment Management Ltd.

1,013,376

0.52%

-1,091

0.15%

03/29/2018

OppenheimerFunds, Inc.

982,356

0.51%

0

0.05%

02/28/2018

BlackRock Advisors (UK) Ltd.

876,383

0.45%

2,250

0.03%

09/06/2018

About UCB

View Profile

Address	Allée de la Recherche, 60 Brussels BU 1070 Belgium
Employees	-
Website	http://www.ucb.com
Updated	07/08/2019
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.